1 DNA Way
South San Francisco
About Genentech, Inc.
Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for over 40 years. Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. We are among the world's leading biotech companies, with multiple products on the market and a promising development pipeline. Please take this opportunity to learn about Genentech where we believe that our employees are our most important asset & are dedicated to remaining a great place to work.
Connect with us!
Being a scientist at Genentech means being a drug discoverer. Mike Varney, head of Genentech Research and Early Development, explains how this culture of innovation is helping to solve some of the hardest biomedical problems of our time.
1439 articles with Genentech, Inc.
Genentech to Present New Data Across 16 Blood Disorders at the American Society of Hematology 2020 Annual Meeting
– New data for Genentech’s CD20xCD3 bispecific antibodies will be featured, as well as first clinical data on cevostamab, a first-of-its-kind FcRH5xCD3 bispecific antibody, in multiple myeloma – – Longer-term data for Genentech’s approved therapies in hemophilia A, chronic lymphocytic leukemia and diffuse large B-cell lymphoma reinforce the favorable efficacy and safety profile of each medicine –
Lodo Therapeutics Achieves Second Preclinical Milestone In Its Strategic Collaboration With Genentech
Lodo's Informatics-Enabled Drug Discovery Platform Accesses the Vast Collections of Undiscovered Drug-Like Molecules Encoded in Microbial DNA
GO2 Foundation for Lung Cancer "Simply the Best" XV Virtual Gala Honors Those Working on the Front Lines to Fight Lung Cancer
GO2 Foundation for Lung Cancer announced it will celebrate Genentech with the "Simply the Best Award" at its XV Virtual Annual Simply the Best Gala on November 14, 2020 at 6:30 pm PT.
Genesis Therapeutics, a privately-held company inventing and deploying state-of-the-art artificial intelligence techniques to augment drug discovery and development, announced that it has entered into a multi-target collaboration agreement with Genentech, a member of the Roche Group.
In this multi-target partnership, Genentech will leverage Genesis’ Dynamic PotentialNet AI platform and other novel neural network algorithms.
Collaboration to advance a first-in-class α9/α10 nAchR antagonist for the treatment of chronic pain into Phase 1 clinical trials
Forbion Portfolio Company, Enterprise Therapeutics’ First-in-Class TMEM16A Potentiator Program for Treatment of Cystic Fibrosis and Other Respiratory Diseases Acquired by Roche
Forbion, a leading European life sciences venture capital firm, announces that its portfolio company, Enterprise Therapeutics Ltd ’s novel TMEM16A potentiator portfolio has been fully acquired by Roche and will be developed by Genentech, a member of the Roche Group.
Enterprise Therapeutics’ First-in-Class TMEM16A potentiator program for treatment of cystic fibrosis and other respiratory diseases acquired by Roche
Enterprise’s novel TMEM16A potentiator portfolio includes ETD002, a first in class compound which is currently in Phase 1
This morning, the Swiss pharma giant acquired a portfolio of experimental cystic fibrosis therapies, including a candidate that has the potential to treat all patients with this disease.
Imbio, a leading provider of artificial intelligence solutions for medical imaging analysis, has partnered with Genentech, a member of the Roche Group, to develop quantitative imaging diagnostics for lung diseases.
Biopharma companies wrapped up September and headed into October with plenty of clinical trial news. Here’s a look.
"We are very excited to have entered into this transformative agreement that marks the start of a new era for Vaccibody,” Michael Engsig, CEO of Vaccibody, said in a statement.
Genentech Presents New 2-Year Data for Evrysdi (risdiplam) in Infants With Type 1 Spinal Muscular Atrophy (SMA)
Exploratory efficacy data showed 88% of infants treated with Evrysdi were alive and did not require permanent ventilation at two years
9/28/2020The European Society of Medical Oncology (ESMO) Virtual Congress 2020 was last weekend and the beginning of the week, which resulted in numerous clinical trial announcements. Here’s a look.
The drug failed to meet its primary efficacy endpoint, as well as two secondary endpoints.
Genentech, a Roche company, presented data from three Phase III trials of Tecentriq (atezolizumab) in triple-negative breast cancer at the European Society for Medical Oncology Virtual Congress 2020 this weekend.
9/21/2020It was a fairly busy week for clinical trial announcements, with some important and interesting news about COVID-19 treatments and vaccines, as well as numerous stories about non-COVID-19 studies.
Genentech Presents New Data From Multiple Phase III Studies of Tecentriq in Triple-Negative Breast Cancer at ESMO Virtual Congress 2020
Data from the Phase III IMpassion031 study demonstrated that Tecentriq in combination with chemotherapy improved pathological complete response for patients with early triple-negative breast cancer (TNBC), when compared to placebo plus chemotherapy
85% of participants in the trial were from minority racial and ethnic groups, which are historically underrepresented in clinical studies.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 18, 2020.